1. Home
  2. SRRK vs KNTK Comparison

SRRK vs KNTK Comparison

Compare SRRK & KNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRRK
  • KNTK
  • Stock Information
  • Founded
  • SRRK 2012
  • KNTK 2017
  • Country
  • SRRK United States
  • KNTK United States
  • Employees
  • SRRK N/A
  • KNTK N/A
  • Industry
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • KNTK Natural Gas Distribution
  • Sector
  • SRRK Health Care
  • KNTK Utilities
  • Exchange
  • SRRK Nasdaq
  • KNTK Nasdaq
  • Market Cap
  • SRRK 4.2B
  • KNTK 3.5B
  • IPO Year
  • SRRK 2018
  • KNTK N/A
  • Fundamental
  • Price
  • SRRK $43.07
  • KNTK $56.40
  • Analyst Decision
  • SRRK Strong Buy
  • KNTK Buy
  • Analyst Count
  • SRRK 7
  • KNTK 7
  • Target Price
  • SRRK $40.43
  • KNTK $49.00
  • AVG Volume (30 Days)
  • SRRK 1.2M
  • KNTK 534.0K
  • Earning Date
  • SRRK 11-12-2024
  • KNTK 11-06-2024
  • Dividend Yield
  • SRRK N/A
  • KNTK 5.56%
  • EPS Growth
  • SRRK N/A
  • KNTK 221.62
  • EPS
  • SRRK N/A
  • KNTK 2.62
  • Revenue
  • SRRK N/A
  • KNTK $1,446,081,000.00
  • Revenue This Year
  • SRRK N/A
  • KNTK $4.74
  • Revenue Next Year
  • SRRK N/A
  • KNTK $34.50
  • P/E Ratio
  • SRRK N/A
  • KNTK $21.53
  • Revenue Growth
  • SRRK N/A
  • KNTK 20.20
  • 52 Week Low
  • SRRK $6.76
  • KNTK $31.73
  • 52 Week High
  • SRRK $46.19
  • KNTK $62.55
  • Technical
  • Relative Strength Index (RSI)
  • SRRK 69.26
  • KNTK 47.99
  • Support Level
  • SRRK $40.95
  • KNTK $54.31
  • Resistance Level
  • SRRK $44.22
  • KNTK $58.44
  • Average True Range (ATR)
  • SRRK 2.57
  • KNTK 1.66
  • MACD
  • SRRK -0.12
  • KNTK -0.52
  • Stochastic Oscillator
  • SRRK 73.14
  • KNTK 32.07

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

About KNTK Kinetik Holdings Inc.

Kinetik is a midstream operator that provides gathering and processing services to gas and oil producers as well as pipeline transportation. It operates exclusively in Texas, serving the Permian Basin and connecting fields with market hubs and other large pipelines. In addition to directly operating pipelines, Kinetik also holds ownership stakes in several pipelines that transport molecules to the Gulf Coast enabling it to obtain exposure to export markets and international demand.

Share on Social Networks: